Apricus Bioscience Inc - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 129

Apricus Bioscience Inc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Apricus Bioscience Inc - Product Pipeline Review - H2 2011” provides data on the Apricus Bioscience Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Apricus Bioscience Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Apricus Bioscience Inc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Apricus Bioscience Inc - Brief Apricus Bioscience Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Apricus Bioscience Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Apricus Bioscience Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Apricus Bioscience Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Apricus Bioscience Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Apricus Bioscience Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Apricus Bioscience Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Apricus Bioscience Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Apricus Bioscience Inc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Apricus Bioscience Inc; Apricus Bioscience Inc - Key Therapeutics; Apricus Bioscience Inc - Pipeline Overview and Promising Molecules; Apricus Bioscience Inc - News; Apricus Bioscience Inc - Latest Updates; Apricus Bioscience Inc - Pipeline; Apricus Bioscience Inc - Discontinued/Dormant Projects

List of Tables
List of Figures
Apricus Bioscience Inc Snapshot
Apricus Bioscience Inc Overview
Key Information
Key Facts
Apricus Bioscience Inc – Research and Development Overview
Key Therapeutic Areas
Apricus Bioscience Inc – Pipeline Review
Pipeline Products by Stage of Development
Apricus Bioscience Inc – Pipeline Products Glance
Apricus Bioscience Inc – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Apricus Bioscience Inc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Apricus Bioscience Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Apricus Bioscience Inc – Drug Profiles
Femprox
Product Description
Mechanism of Action
R&D Progress
Fluorouracil
Product Description
Mechanism of Action
R&D Progress
Ketoprofen
Product Description
Mechanism of Action
R&D Progress
Lidocaine
Product Description
Mechanism of Action
R&D Progress
MycoVa
Product Description
Mechanism of Action
R&D Progress
NM100120
Product Description
Mechanism of Action
R&D Progress
Paclitaxel
Product Description
Mechanism of Action
R&D Progress
PrevOnco
Product Description
Mechanism of Action
R&D Progress
PrevOnco + Doxorubicin
Product Description
Mechanism of Action
R&D Progress
PsoriaVa
Product Description
Mechanism of Action
R&D Progress
RayVa
Product Description
Mechanism of Action
R&D Progress
Rituxan
Product Description
Mechanism of Action
R&D Progress
Vitaros
Product Description
Mechanism of Action
R&D Progress
Apricus Bioscience Inc – Pipeline Analysis
Apricus Bioscience Inc – Pipeline Products by Therapeutic Class
Apricus Bioscience Inc - Pipeline Products By Target
Apricus Bioscience Inc – Pipeline Products by Route of Administration
Apricus Bioscience Inc – Pipeline Products by Molecule Type
Apricus Bioscience Inc – Recent Pipeline Updates
Apricus Bioscience Inc - Dormant Projects
Apricus Bioscience Inc – Company Statement
Apricus Bioscience Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Apricus Bioscience Inc - Key Manufacturing Facilities
Recent Developments
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
Mar 31, 2011: Apricus Bio Expands Patent Coverage In Mexico For Vitaros
Jan 31, 2007: NexMed Announces Patient Dosing In Phase 3 Program For Anti-Fungal Product
Mar 29, 2010: Nexmed Files Investigational New Drug Application For Cancer Drug Candidate PrevOnco
Mar 29, 2010: Nexmed Files Investigational New Drug Application With FDA For Cancer Drug Candidate
Jun 28, 2011: Apricus Announces Acceptance Of Marketing Application For Review Of Vitaros In Erectile Dysfunction
Sep 27, 2004: NexMed Announces IND Filing Of NM100060 For Nail Fungal Infection
Jun 27, 2011: Apricus Bio Reports Reanalysis Of US Phase III Trials For MycoVa
Apr 27, 2011: Apricus Biosciences Requests Approval Of Vitaros As Treatment For Erectile Dysfunction In EUROPE
Aug 26, 2008: NexMed Not To File Drug Application With The Food And Drug Administration
Apr 26, 2010: Nexmed Receives FDA Clearance For Prevonco Phase II Study As First-Line Therapy For HCC
Aug 25, 2005: NexMed Announces Positive Results Of NM100060
Aug 25, 2004: NexMed To Present At The International Society For The Study Of Women's Sexual Health
Sep 24, 2007: Nexmed Files NDA For Proprietary Erectile Dysfunction Treatment
Jun 24, 2010: Nexmed Receives First Patent For Vitaros In Japan
Aug 23, 2011: Apricus Bio Announces FDA Clearance For Hydrocortisone-D Containing NexACT Technology
Jun 23, 2010: NexMed Receives Screening Acceptance Letter From Health Canada For Vitaros
Apr 23, 2010: Nexmed Files CMC Response With Health Canada For Vitaros
Nov 22, 2010: Apricus Files Phase III Registration Protocol For PrevOnco For Special Protocol Consideration By FDA
Oct 22, 2007: Nexmed Files NDS In Canada For Topical Alprostadil Treatment For Erectile Dysfunction
Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
Jul 22, 2008: Nexmed Receives FDA Response For ED Product
Apr 22, 2010: NexMed Files CMC Response With Health Canada For Vitaros
Mar 22, 2004: Nexmed Reports Positive Results For Early Ejaculation Product
Mar 22, 2004: Nexmed Reports Positive Results For NM100061
Apr 21, 2004: Nexmed Announces 5th Patent Allowance For Femprox
Nov 20, 2007: Nexmed Confirms FDA Acceptance Of NDA For Erectile Dysfunction Product
Oct 20, 2008: Nexmed Discusses End Of Review Meeting For Vitaros
Oct 19, 2011: Apricus Biosciences Receives Korean Patent For Vitaros
Jul 19, 2011: Apricus Files Marketing Application For Vitaros As Treatment For Erectile Dysfunction In Switzerland
Feb 19, 2004: NexMed Announces Femprox License Agreement For South Korea
Jan 19, 2011: Apricus Bio Reports Additional Analysis Data On MycoVa For Treatment Of Nail Fungus
Jan 19, 2010: NexMed Provides Updates On Canadian Approval Process For Vitaros
Oct 18, 2010: Apricus Bio Receives First Patent Grant For Femprox In Japan
Aug 18, 2011: Apricus Biosciences Gets FDA Approval For Anti-Fungal Drug Tolnaftate-D
May 18, 2011: Apricus Bio To Request Approval For Vitaros As Treatment For Erectile Dysfunction In Switzerland
May 17, 2010: Nexmed Receives INDA Number For Nexact-Based Alprostadil Treatment For Raynaud's Syndrome From FDA
Feb 17, 2011: Apricus Biosciences And FDA Initiate PrevOnco SPA Phase III Clinical Protocol Discussion
Nov 15, 2010: Apricus Biosciences Receives Canadian Approval For Vitaros As First Line Therapy For Erectile Dysfunction
Nov 15, 2004: NexMed Closes Enrollment For 400 Patient Femprox Study
Sep 15, 2005: NexMed Enters Into Licensing Agreement With Novartis International Pharmaceutical Ltd. To Develop NM100060
Aug 15, 2011: Apricus Biosciences Announces Expansion Of NexACT Patent Portfolio
Jun 15, 2010: Nexmed Announces Preclinical Results Of Calcipotri 0.005% And Betamethasone For Treatment Of Psoriasis
Dec 14, 2006: NexMed Partner, Novartis, Commences Patient Screening For Phase 3 Clinical Trial Of NM100060
Oct 14, 2010: Apricus Bio Announces IND Filing For Nupen
Oct 14, 2009: NexMed Provides Update On Anti-Fungal Product NM100060
Mar 14, 2005: NexMed Provides Update On NM100060 Phase 1 U.S. Study
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
May 12, 2010: NexMed Announces Pre-Clinical Study Results Showing Vitaros Significantly Promotes Wound Healing
Oct 10, 2011: Apricus Biosciences Announces Presentation Of Efficacy And Clinical Safety Data For Vitaros At Upcoming Industry Conference
Jun 10, 2010: Nexmed Provides Update On Canadian Filing For Vitaros
Feb 10, 2011: Apricus Bio To Present Review Of Commercialization Plans For Vitaros And Development Of Product Pipeline At BioPartnering North America Conference
Jul 09, 2007: NexMed Announces Completion Of Patient Enrollment In Two Pivotal Phase 3 Studies For Anti-Fungal Product
Aug 08, 2011: Apricus Biosciences To File For Market Authorization To Sell Vitaros For Erectile Dysfunction In Latin America
Oct 06, 2011: Apricus Biosciences To Present Poster Of Femprox Phase III Clinical Data At Upcoming Industry Conference
May 04, 2005: NexMed Completes U.S. Phase 1 Study For NM100060, A Topical Treatment For Onychomycosis
Apr 04, 2005: NexMed Completes Enrollment For Study Of NM100060
Oct 03, 2011: Apricus Biosciences Announces Korean Patent Approval For MycoVa For Nail Fungus
Jun 03, 2011: Apricus Bio's CEO To Present Commercialization Plans For Vitaros At Jefferies 2011 Global Healthcare Conference
Feb 03, 2009: NexMed Announces Sale Of U.S. Rights For Topical Erectile Dysfunction Treatment
Mar 02, 2004: NexMed To Initiate 400 Femprox Clinical Study In China For Female Sexual Arousal Disorder (FSAD)
Feb 02, 2005: NexMed Initiates Enrollment In U.S. Phase 1 Clinical Study Of NM10060 - A Topical Treatment For Onychomycosis
Mar 01, 2011: Apricus Biosciences Announces Expanded European Patent Coverage For Mycova For Nail Fungus
Feb 01, 2008: NexMed Announces Presentation Of Data At The 66th Annual Meeting Of The American Academy Of Dermatology
Financial Deals Landscape
Apricus Bioscience Inc, Deals Summary
Apricus Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
CJ Enters Into Licensing Agreement With NexMed
Pharmaceutics International Enters Into Collaboration Agreement With NexMed
NexMed Enters Into Research Agreement With Japanese Pharmaceutical Company
Licensing Agreements
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharmaceuticals For Vitaros
Apricus Biosciences Enters Into Licensing Agreement With Bracco
Warner Chilcott Enters Into License Agreement With NexMed
Novartis Enters Into Licensing Agreement With NexMed
Argus Health Enters Into Licensing Agreement With Bio-Quant
NexMed Enters Into Licensing Agreement With Schering
Equity Offering
Apricus Biosciences Announces Rights Offering
Apricus Biosciences Completes Private Placement Of $9.3 Million
NexMed Completes Public Offering For $9.34 Million
NexMed Completes Private Placement Of Common Stock For $6 Million
NexMed Completes Private Placement Of $9 Million
NexMed Completes Private Placement Of $8 Million
NexMed Completes Private Placement Of Preferred Stock For $4 Million
NexMed Completes Private Placement Of $7 Million
Nexmed Completes Private Placement Of $8 Million
Debt Offering
NexMed Completes Private Placement Of Convertible Notes For $0.75 Million
NexMed Completes Convertible Notes Offering Of $5.75 Million
Nexmed Completes 8% Senior Secured Notes Offering For $3 Million
NexMed Completes Private Placement Of $2 Million Secured Senior Note
Asset Transactions
Warner Chilcott Acquires Topical Alprostadil From Nexmed
Acquisition
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences
NexMed Acquires Bio-Quant
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Apricus Bioscience Inc – Pipeline by Therapy Area and Indication, H2 2011
Apricus Bioscience Inc – Pipeline by Stage of Development, H2 2011
Apricus Bioscience Inc – Filed, H2 2011
Apricus Bioscience Inc – Phase III, H2 2011
Apricus Bioscience Inc - Phase II, H2 2011
Apricus Bioscience Inc - Pipeline By Therapeutic Class, H2 2011
Apricus Bioscience Inc - Pipeline By Target, H2 2011
Apricus Bioscience Inc – Pipeline By Route of Administration, H2 2011
Apricus Bioscience Inc – Pipeline By Molecule Type, H2 2011
Apricus Bioscience Inc – Recent Pipeline Updates, H2 2011
Apricus Bioscience Inc - Dormant Developmental Projects, 2010
Apricus Bioscience Inc, Subsidiaries
Apricus Bioscience Inc, Key Manufacturing Facilities
Apricus Bioscience Inc, Deals Summary
CJ Enters Into Licensing Agreement With NexMed
Pharmaceutics International Enters Into Collaboration Agreement With NexMed
NexMed Enters Into Research Agreement With Japanese Pharmaceutical Company
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharmaceuticals For Vitaros
Apricus Biosciences Enters Into Licensing Agreement With Bracco
Warner Chilcott Enters Into License Agreement With NexMed
Novartis Enters Into Licensing Agreement With NexMed
Argus Health Enters Into Licensing Agreement With Bio-Quant
NexMed Enters Into Licensing Agreement With Schering
Apricus Biosciences Announces Rights Offering
Apricus Biosciences Completes Private Placement Of $9.3 Million
NexMed Completes Public Offering For $9.34 Million
NexMed Completes Private Placement Of Common Stock For $6 Million
NexMed Completes Private Placement Of $9 Million
NexMed Completes Private Placement Of $8 Million
NexMed Completes Private Placement Of Preferred Stock For $4 Million
NexMed Completes Private Placement Of $7 Million
Nexmed Completes Private Placement Of $8 Million
NexMed Completes Private Placement Of Convertible Notes For $0.75 Million
NexMed Completes Convertible Notes Offering Of $5.75 Million
Nexmed Completes 8% Senior Secured Notes Offering For $3 Million
NexMed Completes Private Placement Of $2 Million Secured Senior Note
Warner Chilcott Acquires Topical Alprostadil From Nexmed
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences
NexMed Acquires Bio-Quant

List of Figures
Apricus Bioscience Inc – Pipeline by Therapy Area and Indication, H2 2011
Apricus Bioscience Inc – Pipeline by Stage of Development, H2 2011
Apricus Bioscience Inc – Pipeline By Therapeutic Class, H2 2011
Apricus Bioscience Inc - Pipeline By Target, H2 2011
Apricus Bioscience Inc – Pipeline By Route of Administration, H2 2011
Apricus Bioscience Inc – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Analysis of Google Inc
• Insight into Samsung Electronics' Notebook PC Business Model